COMPARATIVE EFFECTS OF PERIOPERATIVE AND ADJUVANT CHEMOTHERAPY ON OUTCOMES OF OPERABLE GASTRIC CANCER: EXPERIENCE FROM A CANCER CARE CENTER

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04989764

Enrollment

108

Registered

2021-08-04

Start date

2015-01-31

Completion date

2021-02-28

Last updated

2021-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Cancer, Outcomes, Pakistan, Adjuvant Chemotherapy, Perioperative Chemotherapy

Brief summary

* Patients with gastric adenocarcinoma * Comparison: perioperative chemotherapy vs. adjuvant therapy. * Sample size differences between the two groups. * Kaplan meier survival analysis, overall survival and disease free survival

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Inclusion criteria

* We included histologically proven gastric adenocarcinoma patient with operable disease and the patients who completed their prescribed perioperative or adjuvant chemotherapy cycles

Exclusion criteria

* Patients were excluded if they had Tis or T1, N0 disease, inoperable disease, metastatic. In addition, all those who did not undergo adequate lymphadenectomy (\< D2) or had R1 margins following surgery were excluded

Design outcomes

Primary

Measure	Time frame	Description
The overall survival	from January 2015 till December 2019	The overall survival (OS) was defined as the length of the time from date of diagnosis till last follow-up or death
The disease-free survival	from January 2015 till December 2019	The disease free survival (DFS) as the length of the time from date of last treatment which is either perioperative or adjuvant chemotherapy to tumor relapse or death.

Outcome results